0000899243-20-017315.txt : 20200619 0000899243-20-017315.hdr.sgml : 20200619 20200619213143 ACCESSION NUMBER: 0000899243-20-017315 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200617 FILED AS OF DATE: 20200619 DATE AS OF CHANGE: 20200619 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Svoronos Dawn CENTRAL INDEX KEY: 0001574579 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 20977061 MAIL ADDRESS: STREET 1: C/O MEDIVATION, INC. STREET 2: 525 MARKET ST., 36TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94105 FORMER NAME: FORMER CONFORMED NAME: Graham Dawn DATE OF NAME CHANGE: 20130416 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-17 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001574579 Svoronos Dawn C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2020-06-17 4 M 0 4800 A 4800 D Common Stock 2020-06-19 4 S 0 1663 63.6881 D 3137 D Common Stock 2020-06-19 4 S 0 881 64.4154 D 2256 D Restricted Stock Units 2020-06-17 4 M 0 4800 0.00 A Common Stock 4800 0 D Stock Option (Right to Buy) 64.75 2020-06-17 4 A 0 5247 0.00 A 2030-06-16 Common Stock 5247 5247 D Restricted Stock Units 2020-06-17 4 A 0 3037 0.00 A Common Stock 3037 3037 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of Issuer's Common Stock sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2020, for the Reporting Person's taxes in connection with the vesting of 4,800 shares of Common Stock underlying the Reporting Person's RSUs. Represents weighted average sales price. The shares were sold at prices ranging from $63.23 to $63.88. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Represents weighted average sales price. The shares were sold at prices ranging from $64.24 to $64.60. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2020 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). /s/ Tricia Suvari, as Attorney-in-Fact 2020-06-19